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A perspective for the cost analysis was not reported, as the authors carried out a very basic evaluation comparing the direct costs associated with usage of the two drugs. A more thorough analysis might have accounted for differences in the times to administer the drugs and potentially costly side effects. Although basic, the analysis was clearly reported, with unit costs and dosage quantities enabling the reader to gain a good understanding of the analysis carried out. Since a price year was not reported, it will not be possible to reflate the cost estimates to different years.
Other issues
The authors were able to draw effectiveness comparisons between their own work and that of other authors involved in randomised controlled studies, as well as open-label observation studies. Their findings seem to have been consistent, with no difference found in the mean change in Hb. The issue of generalisability was not addressed and, though improved by the use of British Columbia contract prices rather than institution specific prices, it is limited by the factor mentioned above. The results presented relate well to the objectives set out by the authors, and do not appear to have been presented selectively. However, a more detailed cost analysis may prove more informative in future. Several limitations, which focused on the non-randomised open-label design of the study, were highlighted.
